NOVAVAX INC (62)

Browse by Contract Category

Contracts

Statement of Work No. 1 to the Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
Modification No. 01 to Base Agreement between Novavax, Inc. and Advanced Technology International, dated as of March 23, 2022 (Filed With SEC on May 10, 2022)
Description of (Filed With SEC on March 1, 2022)
Amendment to Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and the Company, dated June 22, 2021 (Filed With SEC on March 1, 2022)
Amended and Restated Supply and License Agreement, dated July 1, 2021, between Novavax, Inc. and Serum Institute of India Private Limited (Filed With SEC on November 5, 2021)
Employment Agreement, dated July 12, 2021, between Novavax, Inc. and James P. Kelly (Filed With SEC on November 5, 2021)
Amendment No. 1 to the Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
Contract Development Manufacture Agreement (Filed With SEC on August 9, 2022)
Change Order No. 1 to the Collaboration and Exclusive License Agreement between Novavax, Inc. and SK Bioscience Company Limited, dated as of March 31, 2022 (Filed With SEC on May 10, 2022)
Amendment to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
Supply Agreement between the Company, Serum Institute of India Private Limited and Serum Life Sciences Limited, executed as of October 26, 2021 (Filed With SEC on March 1, 2022)
Amendment to Advance Purchase Agreement between the Company, and the Commonwealth of Australia as represented by the Department of Health, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
Statement of Work No. 1 to Collaboration and Exclusive License Agreement between the Company and SK bioscience Company Limited, dated as of December 23, 2021 (Filed With SEC on March 1, 2022)
Modification No. 12 to Undefinitized Project Agreement No. 01, dated December 20, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2022)
Modification No. 13 to Undefinitized Project Agreement No. 01, dated February 1, 2022, between the Company and Advanced Technology International (Filed With SEC on March 1, 2022)
Offer letter to James P. Kelly dated July (Filed With SEC on November 5, 2021)
Consulting Agreement, dated August 10, 2021, between Novavax, Inc. and Gregory F. Covino (Filed With SEC on November 5, 2021)
Modification No. 11 to Undefinitized Project Agreement No. 1, dated August 26, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
Modification No. 09 to Undefinitized Project Agreement No. 1, dated July 16, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
Modification No. 10 to Undefinitized Project Agreement No. 1, dated August 6, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on November 5, 2021)
Advance Purchase Agreement, dated August 16, 2021, between Novavax, Inc., Novavax CZ and the European Commission (Filed With SEC on November 5, 2021)
Modification No. 08 to Undefinitized Project Agreement No. 1, dated June 4, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on August 5, 2021)
Modification No. 07 to Undefinitized Project Agreement No. 1, dated April 23, 2021, between Novavax, Inc. and Advanced Technology International (Filed With SEC on August 5, 2021)
Advance Purchase Agreement, dated May 5, 2021, between Novavax, Inc. and the Gavi Alliance (Filed With SEC on August 5, 2021)
Novavax, Inc. Amended and Restated Change in Control Severance Benefit Plan (Filed With SEC on August 5, 2021)
Form of Amendment to Employment Agreement, dated June 17, 2021, between Novavax, Inc. and each of Stanley C. Erck, Gregory M. Glenn, John J. Trizzino and John A. Herrmann, III (Filed With SEC on August 5, 2021)
Employment Agreement, dated April 12, 2021, between Novavax, Inc. and Gregory F. Covino (Filed With SEC on August 5, 2021)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated June 15, 2021 (Filed With SEC on June 15, 2021)
Collaboration and Exclusive License Agreement between Novavax, Inc. and SK Bioscience Company Limited, dated as of February 12, 2021 (Filed With SEC on May 10, 2021)
Collaboration and Exclusive License Agreement between Novavax, Inc. and Takeda Pharmaceutical Company Limited, dated as of February 24, 2021 (Filed With SEC on May 10, 2021)
Amendment Number 1 to the iPDP and Budget of the Outbreak Response Funding Agreement (Step 2), entered into on November 2, 2020, between Novavax, Inc. and the Coalition for... (Filed With SEC on March 1, 2021)
Description of Registrants Securities (Filed With SEC on March 1, 2021)
Amendment of Solicitation/Modification of Contract, Modification No. 3, entered into January 5, 2021, between the Company and the U.S. Department of Defense Joint Program... (Filed With SEC on March 1, 2021)
Amendment of Solicitation/Modification of Contract, Modification No. 2, entered into December 1, 2020, between the Company and the U.S. Department of Defense Joint Program... (Filed With SEC on March 1, 2021)
Modification No. 06 to Undefinitized Project Agreement No. 01, entered into January 19, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
Modification No. 05 to Undefinitized Project Agreement No. 01, dated January 12, 2021, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
Modification No. 04 to Undefinitized Project Agreement No. 01, entered into December 23, 2020, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
Modification No. 03 to Undefinitized Project Agreement No. 01, entered into September 18, 2020, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
Modification No. 02 to Undefinitized Project Agreement No. 01, entered into September 10, 2020, between the Company and Advanced Technology International (Filed With SEC on March 1, 2021)
Advance Purchase Agreement, effective as of January 19, 2021, between Novavax, Inc. and Her Majesty the Queen in Right of Canada, as represented by the Minister of Public Works... (Filed With SEC on March 1, 2021)
Advance Purchase Agreement, effective as of December 31, 2020, between Novavax, Inc. and the Commonwealth of Australia as represented by the Department of Health (Filed With SEC on March 1, 2021)
SARS-CoV-2 Vaccine Supply Agreement, effective as of October 22, 2020, between Novavax, Inc. and The Secretary of State for Business, Energy and Industrial Strategy, acting on... (Filed With SEC on March 1, 2021)
Deed of Lease for space at 700 Quince Orchard Road between ARE-MARYLAND NO. 51, LLC and Novavax, Inc., dated October 22, 2020 (Filed With SEC on March 1, 2021)
Offer letter to Gregory F. Covino dated October 30, 2020 (Filed With SEC on March 1, 2021)
Employment Agreement between Novavax, Inc. and Gregory F. Covino dated October 30, 2020 (Filed With SEC on March 1, 2021)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated January 22, 2021 (Filed With SEC on January 22, 2021)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley Securities, Inc., dated November 10, 2020 (Filed With SEC on November 10, 2020)
Letter Contract, entered into on June 8, 2020, by and between the Company and the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological... (Filed With SEC on August 10, 2020)
Share Purchase Agreement, dated May 27, 2020, by and among the Company (solely as guarantor), Novavax AB, De Bilt Holdings B.V., Poonawalla Science Park B.V., Bilthoven... (Filed With SEC on August 10, 2020)
Restated Funding Agreement, entered into on May 11, 2020, by and between the Company and the Coalition for Epidemic Preparedness Innovations (Filed With SEC on August 10, 2020)
Series A Convertible Preferred Subscription Agreement, dated as of June 15, 2020, by and between the Company and RA Capital Healthcare Fund, L.P (Filed With SEC on June 19, 2020)
Form of Series A Convertible Preferred Stock Certificate (Filed With SEC on June 19, 2020)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated May 18, 2020 (Filed With SEC on May 18, 2020)
Amended and Restated 2013 Employee Stock Purchase Plan (Filed With SEC on May 11, 2020)
Description of Registrants Securities (Filed With SEC on March 11, 2020)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated March 2, 2020 (Filed With SEC on March 2, 2020)
At Market Issuance Sales Agreement between Novavax, Inc. and B. Riley FBR, Inc., dated January 21, 2020 (Filed With SEC on January 21, 2020)
Form of Stock Appreciation Right Award Agreement granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on November 7, 2019)
Asset Purchase Agreement between Novavax, Inc. and Paragon Bioservices, Inc. dated June 26, 2019 (Filed With SEC on August 7, 2019)
Lease Extension for space at 9920 Belward Campus Drive between Novavax, Inc. and ARE-Maryland No. 46, LLC, dated April 26, 2019 (Filed With SEC on May 2, 2019)
Fifth Amendment to Lease Agreement for space at 9920 Belward Campus Drive between ARE-MARYLAND NO. 46, LLC and Novavax, Inc., dated January 16, 2019 (Filed With SEC on March 18, 2019)
Form of Restricted Stock Unit Agreement granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan (Filed With SEC on March 18, 2019)